Trevena Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.6801
- Today's High:
- $0.735
- Open Price:
- $0.7275
- 52W Low:
- $0.537
- 52W High:
- $5.4825
- Prev. Close:
- $0.75
- Volume:
- 342076
Company Statistics
- Market Cap.:
- $10.28 million
- Book Value:
- 0.713
- Revenue TTM:
- $2.59 million
- Operating Margin TTM:
- -1599.69%
- Gross Profit TTM:
- $-3436000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -49.94%
- Return on Equity TTM:
- -166.79%
Company Profile
Trevena Inc had its IPO on 2014-01-31 under the ticker symbol TRVN.
The company operates in the Healthcare sector and Biotechnology industry. Trevena Inc has a staff strength of 35 employees.
Stock update
Shares of Trevena Inc opened at $0.73 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.68 - $0.74, and closed at $0.72.
This is a -3.6% slip from the previous day's closing price.
A total volume of 342,076 shares were traded at the close of the day’s session.
In the last one week, shares of Trevena Inc have slipped by -18.4%.
Trevena Inc's Key Ratios
Trevena Inc has a market cap of $10.28 million, indicating a price to book ratio of 0.5689 and a price to sales ratio of 106.0323.
In the last 12-months Trevena Inc’s revenue was $2.59 million with a gross profit of $-3436000 and an EBITDA of $-41079000. The EBITDA ratio measures Trevena Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Trevena Inc’s operating margin was -1599.69% while its return on assets stood at -49.94% with a return of equity of -166.79%.
In Q2, Trevena Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 70%.
Trevena Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-3.92 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Trevena Inc’s profitability.
Trevena Inc stock is trading at a EV to sales ratio of 18.7956 and a EV to EBITDA ratio of 0.1324. Its price to sales ratio in the trailing 12-months stood at 106.0323.
Trevena Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $38.86 million
- Total Liabilities
- $8.18 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Trevena Inc ended 2024 with $38.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $38.86 million while shareholder equity stood at $9.78 million.
Trevena Inc ended 2024 with $0 in deferred long-term liabilities, $8.18 million in other current liabilities, 14000.00 in common stock, $-563603000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $28.10 million and cash and short-term investments were $28.10 million. The company’s total short-term debt was $954,000 while long-term debt stood at $14.18 million.
Trevena Inc’s total current assets stands at $32.97 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.53 million and inventory worth $901000.00.
In 2024, Trevena Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Trevena Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.72
- 52-Week High
- $5.4825
- 52-Week Low
- $0.537
- Analyst Target Price
- $6.5
Trevena Inc stock is currently trading at $0.72 per share. It touched a 52-week high of $5.4825 and a 52-week low of $5.4825. Analysts tracking the stock have a 12-month average target price of $6.5.
Its 50-day moving average was $0.92 and 200-day moving average was $1.23 The short ratio stood at 2.83 indicating a short percent outstanding of 0%.
Around 109.5% of the company’s stock are held by insiders while 881.4% are held by institutions.
Frequently Asked Questions About Trevena Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.